Radiopharm Theranostics Limited American Depositary Shares Market Cap ($15.62 Million)
Market Cap & Net Worth: Radiopharm Theranostics Limited American Depositary Shares (RADX)
Radiopharm Theranostics Limited American Depositary Shares market cap. Radiopharm Theranostics Limited American Depositary Shares (NASDAQ:RADX) has a market capitalization of $15.62 Million ($15.62 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25723 globally and #5423 in its home market, demonstrating a 13.68% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Radiopharm Theranostics Limited American Depositary Shares's stock price $1.08 by its total outstanding shares 14458498 (14.46 Million). Also see RADX cash flow conversion for how efficiently the company converts equity into cash flow.
Radiopharm Theranostics Limited American Depositary Shares Market Cap History (2026–2026)
Radiopharm Theranostics Limited American Depositary Shares market cap history from 2026 to 2026. Data shows growth from $15.62 Million to $15.62 Million (0.00% CAGR). Check Radiopharm Theranostics Limited American stock quote for real-time trading data and today's change.
Radiopharm Theranostics Limited American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Radiopharm Theranostics Limited American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RADX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
5.77x
Radiopharm Theranostics Limited American Depositary Shares's market cap is 5.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2026 | $15.62 Million | $2.71 Million | -$53.94 Million | 5.77x | N/A |
Competitor Companies of RADX by Market Capitalization
Companies near Radiopharm Theranostics Limited American Depositary Shares in the global market cap rankings as of November 1, 2026. Also see RADX total assets for a full breakdown of the balance sheet.
Key companies related to Radiopharm Theranostics Limited American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Radiopharm Theranostics Limited American Depositary Shares (2026–2026)
Market capitalization of Radiopharm Theranostics Limited American Depositary Shares from 2026 to today. Between 2026 and today, Radiopharm Theranostics Limited American Depositary Shares's market cap moved from $15.62 Million to $ 15.62 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $15.62 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Radiopharm Theranostics Limited American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.62 Million USD |
| MoneyControl | $15.62 Million USD |
| MarketWatch | $15.62 Million USD |
| marketcap.company | $15.62 Million USD |
| Reuters | $15.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more